Call Us Now

+91 9606900005 / 04

For Enquiry

legacyiasacademy@gmail.com

Cervavac

Context:

The Serum Institute of India (SII)’s vaccine Cervavac recently received the Drugs Controller General of India’s (DGCI) approval for market authorisation.

Relevance:

GS III- Science and Technology

Dimensions of the Article:

  1. About Cervavac
  2. About Cervical cancer

About Cervavac:

  • Cervavac is India’s first quadrivalent human papillomavirus vaccine (qHPV) vaccine, and intended to protect women against cervical cancer.
  • Experts see this as a real opportunity to eliminate cervical cancer, and have expressed the hope that it will be rolled out in national HPV vaccination strategies, and be available a cost more affordable than existing vaccines.
  • The vaccine is based on VLP (virus like particles), similar to the hepatitis B vaccine, and provides protection by generating antibodies against the HPV virus’s L1 protein.
  • Experts have expressed hope that the DGCI approval will allow the government to procure enough HPV vaccines at a special price to vaccinate nearly 50 million girls aged 9–14 years in India who are waiting to receive the vaccine.
  • This will be a huge step to accelerate cervical cancer elimination in India and globally, a statement from IARC-WHO has said.

About Cervical cancer:

  • Cervical cancer is preventable, but kills one woman every eight minutes in the country.
  • It is preventable as long as it is detected early and managed effectively.
  • Cervical cancer is a common sexually transmitted infection.
  • Long-lasting infection with certain types of HPV is the main cause of cervical cancer.
  • Worldwide, cervical cancer is the second most common cancer type and the second most common cause of cancer death in women of reproductive age (15–44).
  • India accounts for about a fifth of the global burden, with 1.23 lakh cases and around 67,000 deaths per year according to the World Health Organization’s International Agency for Research on Cancer (IARC-WHO).

Existing vaccines

  • Two vaccines licensed globally are available in India — a quadrivalent vaccine (Gardasil, from Merck) and a bivalent vaccine (Cervarix, from GlaxoSmithKline).
  • Although HPV vaccination was introduced in 2008, it has yet to be included in the national immunisation programme.

-Source: Indian Express


Download PDF
November 2022
MTWTFSS
 123456
78910111213
14151617181920
21222324252627
282930 
Categories